Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder

CNS Neuroscience & Therapeutics
Samaneh KabulDavid B Clemow

Abstract

The aim was to investigate the dosing patterns of atomoxetine monotherapy in adult patients with attention-deficit/hyperactivity disorder (ADHD) in a retrospective analysis. Adult (≥ 18 years) patients with ADHD newly initiated on atomoxetine with ≥ 1 outpatient pharmacy claim for atomoxetine between January 2006 and December 2011 were selected from the Truven Health MarketScan(®) Commercial database. After a 30-day titration period, dosing patterns of atomoxetine monotherapy were analyzed in the 12 months following initiation. In addition, patient demographic and clinical characteristics were compared to identify characteristics associated with suboptimal versus recommended dosing. Of the 12,412 adult patients with ADHD newly initiated on atomoxetine, 4548 (36.6%) were suboptimally dosed, whereas 3323 (26.7%) were treated at recommended dose. Overall, study patients were treated at a mean (standard deviation [SD]) dose of 68.5 (44.9) mg/day. The suboptimal dosing cohort included significantly more females (54% vs. 44%, P < 0.001) and had fewer patients with pre-index use of other ADHD medications (17% vs. 20%, P < 0.001) compared with the recommended dosing cohort. Adult patients with ADHD receiving atomoxetine therapy in a re...Continue Reading

References

Mar 1, 1993·Psychosomatic Medicine·L Keltikangas-JärvinenT Lehtimäki
Nov 9, 2000·Journal of the American Academy of Child and Adolescent Psychiatry·P Rasmussen, C Gillberg
Jan 28, 2003·Biological Psychiatry·David MichelsonDenái Milton
Jun 16, 2004·Archives of Internal Medicine·Stephen V FaraoneJoseph Biederman
Jul 19, 2005·Lancet·Joseph Biederman, Stephen V Faraone
Feb 19, 2008·The American Journal of Psychiatry·Jeffrey H NewcornUNKNOWN Atomoxetine/Methylphenidate Comparative Study Group
May 2, 2008·Journal of Attention Disorders·Lenard A AdlerDavid Michelson
Aug 30, 2008·Neuropsychiatric Disease and Treatment·Dusan KolarLily Hechtman
Jan 15, 2009·Journal of Clinical Psychopharmacology·Lenard A AdlerDouglas Kelsey
Oct 1, 2011·Expert Review of Neurotherapeutics·Timothy E WilensJefferson Prince
Oct 2, 2012·Journal of the American Academy of Child and Adolescent Psychiatry·Jalpa A DoshiPeter J Neumann
Oct 9, 2014·Postgraduate Medicine·David B Clemow, Daniel J Walker
Oct 16, 2014·The Primary Care Companion to CNS Disorders·Patricia O Quinn, Manisha Madhoo
Nov 26, 2014·Postgraduate Medicine·David B Clemow
Dec 3, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mats FredriksenDawn E Peleikis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.